Influence
May 14, 2020

In New York Times opinion piece, Regenstrief VP presents COVID-19 data recommendations for states

As states are beginning to reopen in the face of COVID-19, many are doing so without enough data, according to Regenstrief Institute Vice President for Faculty and Development Aaron Carroll, M.D. In a recent opinion column for the New York Times, Dr. Carroll made an exception: Indiana.

He discussed the groundbreaking COVID-19 testing study being led by Regenstrief research scientist and IU Fairbanks School of Public Health faculty member Nir Menachemi, PhD, MPH.

The study, which tested 4,600 people in its first phase, has found that 2.8 percent of Hoosiers are either infected with the coronavirus or have recovered. While these findings suggested a mortality rate of about 0.6 percent, lower than some experts have suggested, the study also indicated that 10 out of 11 cases of COVID-19 in the state’s population are not being caught due to low testing rates.

“We need much more data,” Dr. Carroll writes, “too many states are flying blind, moving ahead without understanding their risk. There’s no excuse for that. There’s no magic to what’s just been done in Indiana. All states could do it if they just committed to it.”

Since early in the pandemic, Dr. Carroll has warned about the potential of the virus to overwhelm the healthcare system and has been an advocate for nationwide social distancing and mass testing of the population as a means to contain the virus.

READ THE ARTICLE

Related News

Gonzalez quote graphic

National Academy of Medicine names Gonzalez a scholar in diagnostic excellence

Regenstrief researcher developing AI methodology to identify asymptomatic patients with leading cause of limb amputation INDIANAPOLIS – Andrew Gonzalez,

Dr. Jennifer Marratt headshot

NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024

Published in Journal of the National Comprehensive Cancer Network. Here is a link to the article. Regenstrief Institute author:

Preparing for widespread use of biomarkers to diagnose Alzheimer’s disease

Factors for consideration include patient characteristics, test accuracy, ethical issues INDIANAPOLIS – For years many people with Alzheimer’s disease